[Adrenal incidentaloma and nuclear medicine examination].
In the setting of adrenal incidentaloma, nuclear medicine evaluation is only indicated after biological and imaging work-up has been completed. MIBG scintigraphy is helpful to characterize pheochromocytomas. In lesions without MIBG uptake, 18F FDG or 18F DOPA PET can be considered to characterize chromaffin cell tumours. To characterize lesions of the adrenal cortex, iodocholesterol scintigraphy is performed to confirm the origin of the adenoma and the benign or malignant nature of the lesion since benign adenomas show tracer uptake and malignant lesions show no tracer uptake. 18F FDG PET only characterizes the lesion as benign or malignant.
Tenenbaum
F
F
Service de Médecine Nucléaire, Hôpital Cochin, 27 rue du Fg Saint-Jacques, 75014 Paris, France. florence.tenenbaum@cch-aphp.fr
D015071:19-Iodocholesterol; D019797:3-Iodobenzylguanidine; D000236:Adenoma / Q000000981:diagnostic imaging*; D000306:Adrenal Cortex Neoplasms / Q000000981:diagnostic imaging*; D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging*; D000328:Adult; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D033162:Incidental Findings; D010673:Pheochromocytoma / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals
D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C043437:fluorodopa F 18; D015071:19-Iodocholesterol; D019797:3-Iodobenzylguanidine; D004295:Dihydroxyphenylalanine